A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor
Clinical trial NCT02412111 · COMPLETED
Trial details
- NCT number
- NCT02412111
- Sponsor
- Vertex Pharmaceuticals Incorporated
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-06-01
- Primary completion
- 2017-09-01
- Enrollment
- 156
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.